
SynAct Pharma Q1 2025 - New Phase II Study in Dengue Fever

Redeye comments on SynAct's Q1 report, which includes the initiation of a new phase II study in Dengue fever and new patents. Costs increased compared with Q4 2024.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[SynAct Pharma Q1 2025 - New Phase II Study in Dengue Fever](#)